- Home
- MG vs TVRD Comparison
MG vs TVRD Comparison
Compare MG & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MG
- TVRD
- Stock Information
- Founded
- MG 1978
- TVRD 2017
- Country
- MG United States
- TVRD United States
- Employees
- MG N/A
- TVRD N/A
- Industry
- MG Military/Government/Technical
- TVRD Biotechnology: Pharmaceutical Preparations
- Sector
- MG Consumer Discretionary
- TVRD Health Care
- Exchange
- MG Nasdaq
- TVRD Nasdaq
- Market Cap
- MG 251.6M
- TVRD 246.5M
- IPO Year
- MG 2009
- TVRD N/A
- Fundamental
- Price
- MG $8.05
- TVRD $26.91
- Analyst Decision
- MG
- TVRD Strong Buy
- Analyst Count
- MG 0
- TVRD 4
- Target Price
- MG N/A
- TVRD $58.50
- AVG Volume (30 Days)
- MG 162.4K
- TVRD 93.4K
- Earning Date
- MG 07-30-2025
- TVRD 08-21-2025
- Dividend Yield
- MG N/A
- TVRD N/A
- EPS Growth
- MG N/A
- TVRD N/A
- EPS
- MG 0.47
- TVRD N/A
- Revenue
- MG $706,813,000.00
- TVRD N/A
- Revenue This Year
- MG $0.81
- TVRD N/A
- Revenue Next Year
- MG $2.93
- TVRD N/A
- P/E Ratio
- MG $17.22
- TVRD N/A
- Revenue Growth
- MG N/A
- TVRD N/A
- 52 Week Low
- MG $7.06
- TVRD $8.13
- 52 Week High
- MG $12.44
- TVRD $34.31
- Technical
- Relative Strength Index (RSI)
- MG 52.70
- TVRD N/A
- Support Level
- MG $7.97
- TVRD N/A
- Resistance Level
- MG $8.37
- TVRD N/A
- Average True Range (ATR)
- MG 0.20
- TVRD 0.00
- MACD
- MG 0.05
- TVRD 0.00
- Stochastic Oscillator
- MG 64.44
- TVRD 0.00
About MG Mistras Group Inc
MISTRAS Group Inc provides asset protection solutions and systems. The company evaluates the structural integrity and reliability of critical energy, industrial, and public infrastructure. The company's three operating segments are North America, International and Products and Systems, of which key revenue is derived from the North America segment. Services segment provides asset protection solutions predominantly in North America, with the large amount of concentration in the United States, followed by Canada, consisting of non-destructive testing, and inspection. The asset protection solutions include field inspections, consulting, maintenance, data management, access, monitoring and laboratory quality assurance.
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.